Diabetes Clinical Trial
— BIGPICOfficial title:
Bridging Income Generation With Group Integrated Care (BIGPIC)
Verified date | June 2020 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Specific Aims: Bridging Income Generation with GrouP Integrated Care (BIGPIC) Over 80% of
cardiovascular disease (CVD) deaths occur in low- and middle-income countries (LMICs).
Diabetes, a major risk factor for CVD, is also responsible for substantial morbidity and
mortality in LMICs. Elevated blood pressure (BP) increases CVD risk among individuals with
diabetes and pre-diabetes; BP control is therefore a powerful way to reduce CVD risk.
Cost-effective, culturally appropriate, and context-specific approaches are critical. Two
promising strategies to improve health outcomes are group medical visits and microfinance.
Both can increase quality of care, clinician-patient trust, self-efficacy, health savings,
self-confidence, group cohesion, and social support. While these strategies have been
successful in other contexts, their impact on CVD risk reduction among diabetics and
pre-diabetics in low-resource settings is not known.
In partnership with the Government of Kenya, the Academic Model Providing Access to
Healthcare (AMPATH) Partnership has expanded its clinical scope of work to include diabetes
and hypertension. AMPATH has piloted group care and microfinance initiatives among patients
with chronic diseases with promising early results. Both strategies are feasible, as is
integration of group medical visits into microfinance groups. However, the effectiveness of
these strategies individually, and in combination, on improving CVD risk is not known.
Thus, the objective of this proposal is to utilize a transdisciplinary implementation
research approach to address the challenge of reducing CVD risk in low-resource settings. The
central hypothesis is: group medical visits integrated into microfinance groups will be
effective and cost-effective in reducing CVD risk among individuals with diabetes and at
increased risk for diabetes in western Kenya, and that the key modifiable CVD risk factor to
be addressed is BP. The research team hypothesize that group medical visits and microfinance
may each reduce CVD risk, but the integration of group medical visits and microfinance will
yield the largest gains. Also further hypothesize is that changes in social network
characteristics may mediate the impact of interventions on the primary outcome, and that
baseline social network characteristics may moderate the impact of interventions. To test
these hypotheses and achieve the overall objectives, the following specific aims will be
pursued:
Aim 1: Identify the contextual factors, facilitators, and barriers that may impact
integration of group medical visits and microfinance for CVD risk reduction, using a
combination of qualitative research methods: 1) baraza (traditional community gathering) form
of inquiry; and 2) focus group discussions among individuals with diabetes or at increased
risk for diabetes, microfinance group members, and rural health workers.
Subsidiary Aim 1.1: Use identified facilitators and barriers to develop a contextually and
culturally appropriate integrated group medical visit-microfinance model to reduce CVD risk
among individuals with diabetes or at increased risk of diabetes. This model's acceptability
and feasibility will be assessed by conducting focus group discussions with patients,
microfinance group members, and health workers.
Aim 2: Evaluate the effectiveness of group medical visits and microfinance groups for CVD
risk reduction among individuals with diabetes or at increased risk for diabetes, by
conducting a four-arm cluster randomized trial comparing: 1) usual clinical care; 2) usual
clinical care plus microfinance groups only; 3) group medical visits only (no microfinance);
and 4) group medical visits integrated into microfinance groups. The primary outcome measure
will be one-year change in systolic blood pressure (SBP), and a key secondary outcome will be
change in QRISK2 CVD risk score, which has been validated for Black Africans.
Subsidiary Aim 2.1: Conduct mediation analysis to evaluate the influence of changes in social
network characteristics on intermediate factors and intervention outcomes and moderation
analysis to evaluate the influence of baseline social network characteristics on
effectiveness of interventions.
Aim 3: Evaluate the incremental cost-effectiveness of each intervention arm of the trial, in
terms of costs per unit decrease in SBP, per percent change in CVD risk score, and per
disability-adjusted life year saved.
This research project will add to the existing knowledge base on innovative, scalable, and
sustainable strategies for reducing CVD risk in diabetes and other chronic diseases in LMICs
and other low-resource settings. If proven to be effective, the investigators are poised to
expand the approach beyond the trial, thus ensuring that this research will have a
significant and positive health impact on a larger population.
Status | Completed |
Enrollment | 2890 |
Est. completion date | December 29, 2019 |
Est. primary completion date | December 29, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 35 Years and older |
Eligibility |
Inclusion criteria: Adults in the CDM Program who: - Have diabetes (fasting glucose = 7 mmol/L); - Are at increased risk for developing diabetes (impaired fasting glucose (fasting glucose 5.6 - 6.9 mmol/L); - Have an elevated Leicester Risk Assessment score (= 7) Exclusion criteria: - Acute illness requiring immediate medical attention; - Terminal illness; - Refusal to provide informed consent; - Individuals who are pregnant or have HIV will be excluded, (automatically referred to a higher level of care within the AMPATH care system). Participation in the trial will not be contingent upon membership in a group. An intention-to-treat analysis will be conducted and the denominator in each cluster will include all eligible individuals who consent, irrespective of whether they are in a group, thus minimizing selection bias. |
Country | Name | City | State |
---|---|---|---|
Kenya | Moi University College of Health Sciences | Eldoret |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health | Brown University, Duke University, Icahn School of Medicine at Mount Sinai, Moi University College of Health Sciences, National Heart, Lung, and Blood Institute (NHLBI), Purdue University |
Kenya,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Systolic Blood Pressure | Change in Systolic Blood Pressure at 12 months as compared to baseline | Baseline and 12 months | |
Secondary | Change in cardiovascular disease (CVD) risk Score | Change in overall CVD risk as measured by the QRISK2 score, which has been validated for calculating 10-year CVD event risk for Black Africans. | Baseline and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |